Related Experiment Videos
Thalidomide: from teratogen to anti-angiogenic
1Department of Pharmacology, All India Institute of Medical Sciences, Ansan Nagar, New Delhi 110029.
Indian Journal of Cancer
|February 5, 2004
Summary
Thalidomide shows therapeutic promise beyond its teratogenic effects due to immunomodulatory and anti-angiogenic properties. Despite mixed results in tumor models, clinical trials show encouraging outcomes for refractory myeloma, suggesting potential in other malignancies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Thalidomide, historically known for teratogenicity, is being re-evaluated for therapeutic applications.
- Its immunomodulatory and anti-angiogenic effects are key to its emerging medical relevance.
- Initial hypotheses suggested efficacy in angiogenesis-dependent tumors based on animal models.
Purpose of the Study:
- To review experimental and clinical evidence of thalidomide's anti-angiogenic and anti-tumor effects.
- To explore the mechanisms of action underlying thalidomide's therapeutic potential.
- To discuss the clinical outcomes of thalidomide in various malignancies.
Main Methods:
- Review of experimental studies on angiogenesis inhibition using assays like the corneal micro-pocket assay.
- Analysis of clinical trial data, particularly focusing on patients with refractory myeloma.
- Examination of in vitro and in vivo studies investigating thalidomide's mechanism of action.
Main Results:
- Thalidomide demonstrated inhibition of experimental angiogenesis in animal models.
- Contrary to expectations, thalidomide did not consistently prevent tumor growth in all tested animal models.
- Clinical studies revealed encouraging results in patients with refractory myeloma.
Conclusions:
- Thalidomide exhibits significant anti-angiogenic and immunomodulatory properties with therapeutic potential.
- While animal models showed variable anti-tumor effects, clinical data, especially for refractory myeloma, are promising.
- Further clinical trials are warranted to explore thalidomide's efficacy across a broader range of malignancies.